Adaptimmune announces Giles Kerr to its board as Independent Non-Executive Director
– USA, PA / UK, Oxford – Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced changes to its Board of Directors with the appointment of Giles Kerr and planned retirement of Ian Laing.…